EGFR and lung cancer: Another work showed that the combination of several techniques, such as fluorescence in situ hybridization (FISH) for detecting ALK rearrangements, Sanger sequencing for EGFR, pyrosequencing for KRAS and BRAF, and next generation sequencing (NGS) using a lung cancer panel was capable to detect genetic abnormalities in 59% of the PF cell blocks from cytologically-proven NSCLC.